Telesis Bio to Present at Jefferies Healthcare Conference 2023
08 Junho 2023 - 10:05AM
Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic
and synthetic biology solutions, announced that Todd R. Nelson,
Ph.D., CEO and Founder of Telesis Bio will present today at the
2023 Jefferies Healthcare Conference, Thursday, June 8,
2023, at 10:00 am Eastern time / 7:00 am Pacific Time.
The live and archived webcast of the presentation will be
accessible from the company’s website at
https://ir.telesisbio.com/news-events/events. The replay of the
webcast will be available for 90 days.
About Telesis BioTelesis Bio is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® system consolidates, automates,
and optimizes the entire synthesis, cloning and amplification
workflow. As a result, it delivers virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp
are trademarks of Telesis Bio Inc.
Forward-Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
include statements and guidance regarding the anticipated use of
proceeds from the financing, as well as statements regarding the
future release and success of new and existing products and
services. Such statements are based on current assumptions that
involve risks and uncertainties that could cause actual outcomes
and results to differ materially. These risks and uncertainties,
many of which are beyond our control, include risks described in
the section entitled Risk Factors and elsewhere in our Annual
Report on Form 10-K, which was filed with the Securities and
Exchange Commission (SEC) on March 22, 2023, as amended on May
17, 2023 and in our Quarterly Report on Form 10-Q, which was filed
with the SEC on May 12, 2023. These forward-looking statements
speak only as of the date hereof and should not be unduly relied
upon. Telesis Bio disclaims any obligation to update these
forward-looking statements.
Contact:Jen CarrollVice President of Investor
Relationsjen.carroll@telesisbio.com
Telesis Bio (NASDAQ:TBIO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Telesis Bio (NASDAQ:TBIO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024